Tirzepatide vs intensified care in early type 2 diabetes: HbA1c results at week 104
In a phase 4 trial record sponsored by Eli Lilly, adults with early type 2 diabetes on tirzepatide had a larger HbA1c fall at week 104 than those on intensified conventional care.

At a glance
- In 794 adults, least squares mean HbA1c change at week 104 was -2.24 percentage points with tirzepatide and -1.45 with intensified conventional care (ICC). The difference was -0.79, p <.001.
- The trial was open-label and sponsored by Eli Lilly and Company. HbA1c is a surrogate outcome.
- This is a registry results record, not a full paper. Safety data and the drugs used in ICC are not in the text available.
Key result
Tirzepatide lowered HbA1c more than intensified conventional care (-2.24% vs -1.45%).
Change in HbA1c from baseline, Week 104
The study
This is the results entry for trial NCT05433584 on ClinicalTrials.gov. The sponsor is Eli Lilly and Company. The design is randomised, open-label, parallel-group and two-arm. The source labels it phase 4. It enrolled 794 adults.
The trial compares tirzepatide with intensified conventional care (ICC) when treatment starts early in the course of type 2 diabetes. The record's summary describes ICC as "other existing treatment options". It does not list which drugs were used. It also does not define "early" in terms of years since diagnosis.
The primary outcome was the change in HbA1c from baseline to week 104.
What they found
The record reports least squares mean changes in HbA1c (unit: percentage of HbA1c) at week 104:
- Tirzepatide: -2.24 (spread 0.053).
- Intensified conventional care: -1.45 (spread 0.052).
HbA1c fell in both groups. The mixed models analysis gave a net least squares mean difference of -0.79, with p <.001. In plain terms, HbA1c fell more with tirzepatide than with ICC, and the difference between the groups was statistically significant.
The record does not state what the "spread" figure is, for example standard error or standard deviation. It does not give a confidence interval for the difference. The text available does not include baseline HbA1c, safety results, weight outcomes or secondary outcomes.
How much weight to give it
Randomisation is a strength of the design, and the trial enrolled 794 adults.
There are important limits:
- The trial was open-label.
- HbA1c is a surrogate outcome. The record does not report hard outcomes such as cardiovascular events or kidney outcomes.
- The trial was sponsored by Eli Lilly and Company.
- This is a registry results record. It is not a peer-reviewed paper, and details may become clearer or change in a full publication.
- The record does not say what ICC contained, so it is hard to judge how fair the comparison was.
- No safety data are in the text available, so the balance of benefit and harm cannot be judged.
For your clinic
The result suggests that starting tirzepatide early in type 2 diabetes lowered HbA1c more by week 104 than a strategy of intensifying other treatments. It should not be used on its own to choose a treatment for an individual patient.
Before changing practice, read the full paper when it is available. Check which drugs made up ICC, how "early" diabetes was defined, who was enrolled, how many people stayed on treatment, and the adverse event and hypoglycaemia data. Also consider cost, patient preference and current guidelines. The record does not show whether the larger HbA1c fall leads to better long-term clinical outcomes.
Source
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Eli Lilly and Company. ClinicalTrials.gov results. 12 November 2026
Cite this report: Diabesity Rounds. Tirzepatide vs intensified care in early type 2 diabetes: HbA1c results at week 104. 2026. doi:10.5281/zenodo.24236977
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on glp-1 and incretin drugs
- CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9Randomised trial · 16 November 2026
- CHMP backs two insulin aspart biosimilars and issues tirzepatide contraceptive adviceRegulatory · 14 November 2026
- Pemvidutide in MASH: non-invasive liver markers improve at 48 weeksRandomised trial · 13 November 2026
- Trevogrumab reduced lean mass loss on semaglutide in phase 2 trialRandomised trial · 13 November 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.